Silent Heart Attack Market Research Report: By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications, Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End-User (Hospital, Clinic, Diagnostic Center) - Global Forecast till 2027
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Silent Heart Attack Market, by Diagnosis
6.1 Introduction
6.2 Cardiac computerized tomography
Market Estimates & Forecast, 2020 – 2027
6.3 magnetic resonance imaging
Market Estimates & Forecast, 2020 – 2027
6.4 electrocardiogram
Market Estimates & Forecast, 2020 – 2027
6.5 echocardiogram
Market Estimates & Forecast, 2020 – 2027
6.6 Blood Test
Market Estimates & Forecast, 2020 – 2027
6.7 Others
Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Silent Heart Attack Market, by Treatment
7.1 Introduction
7.2 Medications
Market Estimates & Forecast, 2020 – 2027
7.3 Coronary angioplasty and stenting
Market Estimates & Forecast, 2020 – 2027
7.5 Coronary artery bypass surgery
Market Estimates & Forecast, 2020 – 2027
7.6 Other
Market Estimates & Forecast, 2020 – 2027
Chapter 8 Global Silent Heart Attack Market, by End User
8.1 Introduction
8.2 Hospital
Market Estimates & Forecast, 2020 – 2027
8.3 Clinics
Market Estimates & Forecast, 2020 – 2027
8.4 Diagnostic Centers
Market Estimates & Forecast, 2020 – 2027
8.5 Others
Market Estimates & Forecast, 2020 – 2027
Chapter 9. Global Silent Heart Attack Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Siemens
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Koninklijke Philips N.V.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 AstraZeneca plc
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sanofi
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Merck & Co.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Silent Heart Attack Industry Synopsis, 2020 – 2027
Table 2 Global Silent Heart Attack Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Silent Heart Attack Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
Table 5 Global Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 6 Global Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 7 North America Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
Table 8 North America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 9 North America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 10 US Market by Diagnosis, 2020 – 2027, (USD Million)
Table 11 US Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 12 US Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 13 Canada Market by Diagnosis, 2020 – 2027, (USD Million)
Table 14 Canada Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 15 Canada Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 16 South America Market by Diagnosis, 2020 – 2027, (USD Million)
Table 17 South America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 18 South America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 19 Europe Market by Diagnosis, 2020 – 2027, (USD Million)
Table 20 Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 21 Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 22 Western Europe Market by Diagnosis, 2020 – 2027, (USD Million)
Table 23 Western Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 24 Western Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 25 Eastern Europe Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 Eastern Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Eastern Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 28 Asia Pacific Market by Diagnosis, 2020 – 2027, (USD Million)
Table 29 Asia Pacific Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 30 Asia Pacific Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
Table 31 Middle East & Africa Market by Diagnosis, 2020 – 2027, (USD Million)
Table 32 Middle East & Africa Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
Table 33 Middle East & Africa Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Silent Heart Attack Market
Figure 3 Segmentation Market Dynamics for Global Silent Heart Attack Market
Figure 4 Global Silent Heart Attack market Share, by Type 2020
Figure 5 Global Silent Heart Attack market Share, by Treatment 2020
Figure 6 Global Silent Heart Attack Market Share, by End Users, 2020
Figure 7 Global Silent Heart Attack Market Share, by Region, 2020
Figure 8 North America Silent Heart Attack Market Share, by Country, 2020
Figure 9 Europe Silent Heart Attack Market Share, by Country, 2020
Figure 10 Asia Pacific Silent Heart Attack Market Share, by Country, 2020
Figure 11 Middle East & Africa Silent Heart Attack Market Share, by Country, 2020
Figure 12 Global Silent Heart Attack Market: Company Share Analysis, 2020 (%)
Figure 13 Siemens: Key Financials
Figure 14 Siemens: Segmental Revenue
Figure 15 Siemens: Geographical Revenue
Figure 16 Koninklijke Philips N.V.: Key Financials
Figure 17 Koninklijke Philips N.V.: Segmental Revenue
Figure 18 Koninklijke Philips N.V.: Geographical Revenue
Figure 19 AstraZeneca plc: Key Financials
Figure 20 AstraZeneca plc: Segmental Revenue
Figure 21 AstraZeneca plc: Geographical Revenue
Figure 22 Pfizer: Key Financials
Figure 23 Pfizer: Segmental Revenue
Figure 24 Pfizer: Geographical Revenue
Figure 25 Sanofi.: Key Financials
Figure 26 Sanofi.: Segmental Revenue
Figure 27 Sanofi.: Geographical Revenue
Figure 28 F. Hoffmann-La Roche Ltd.: Key Financials
Figure 29 F. Hoffmann-La Roche Ltd.: Segmental Revenue
Figure 30 F. Hoffmann-La Roche Ltd.: Geographical Revenue
Figure 31 AstraZeneca Plc: Key Financials
Figure 32 AstraZeneca Plc: Segmental Revenue
Figure 33 AstraZeneca Plc.: Geographical Revenue
Speak to Analyst
Request a Free Sample
Market Synopsis of the Silent Heart Attack Market
Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.
According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.
The Silent Heart Attack Market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.
Silent Heart Attack Market is expected to grow at a CAGR of 5.7% during the forecast period.
Market Segments
Silent Heart Attack Market is segmented on the basis of Diagnosis, Indication, Devices, and End User.
On the basis of diagnosis, market is segmented into cardiac computerized tomography, magnetic resonance imaging, electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, coronary artery bypass surgery, and others.
On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis of the Silent Heart Attack Market
America accounts for the largest market for the silent heart attack. The increasing prevalence of cardiovascular diseases and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the Silent Heart Attack Market.
Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.
In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by the presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.
Silent Heart Attack Market by Type, 2016 (%) 
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders
Key Players in the Silent Heart Attack Market
Some of the key players in Silent Heart Attack Market are Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland).
Research Methodology
Intended Audience
- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Frequently Asked Questions (FAQ) :
silent heart attack market is expected to register 5.7% CAGR from 2020 to 2027.
silent heart attack market is driven by high incidence of cardiovascular diseases.
High costs of diagnosis of heart conditions and lack of skilled professionals are factors which can hamper the global silent heart attack market.
The Americas can dominate the global silent heart attack market till 2023 due to rising cases of cardiovascular diseases.
Toshiba Medical Systems Corporation, Merck & Co., Takeda Pharmaceutical Company Limited, Bayer, Boehringer Ingelheim GmbH, Bionet, Midmark Corporation, Johnson & Johnson, United Therapeutics Corporation, Pfizer, Daiichi Sankyo Company Limited, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Actelion Pharmaceuticals Ltd., Schiller AG, AstraZeneca plc, Sanofi, Welch Allyn, Koninklijke Philips N.V., Novartis AG, and Siemens are notable players of the global silent heart attack market.
